R01AI088748/AI/NIAID NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2011	3
2012	4
2013	4
2014	6
2015	9
2016	1
2024	0

1

Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

Zhang Y, Feng H. Zhang Y, et al. Pathog Dis. 2016 Jun;74(4):ftw024. doi: 10.1093/femspd/ftw024. Epub 2016 Apr 4. Pathog Dis. 2016. PMID: 27044305 Free PMC article. Review.

2

Clostridial toxins: sensing a target in a hostile gut environment.

Oezguen N, Power TD, Urvil P, Feng H, Pothoulakis C, Stamler JS, Braun W, Savidge TC. Oezguen N, et al. Gut Microbes. 2012 Jan-Feb;3(1):35-41. doi: 10.4161/gmic.19250. Epub 2012 Jan 1. Gut Microbes. 2012. PMID: 22356854 Free PMC article. Review.

3

Mouse relapse model of Clostridium difficile infection.

Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Sun X, et al. Infect Immun. 2011 Jul;79(7):2856-64. doi: 10.1128/IAI.01336-10. Epub 2011 May 16. Infect Immun. 2011. PMID: 21576341 Free PMC article.

4

Utility of Clostridium difficile toxin B for inducing anti-tumor immunity.

Huang T, Li S, Li G, Tian Y, Wang H, Shi L, Perez-Cordon G, Mao L, Wang X, Wang J, Feng H. Huang T, et al. PLoS One. 2014 Oct 23;9(10):e110826. doi: 10.1371/journal.pone.0110826. eCollection 2014. PLoS One. 2014. PMID: 25340750 Free PMC article.

5

Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B.

Yuan P, Zhang H, Cai C, Zhu S, Zhou Y, Yang X, He R, Li C, Guo S, Li S, Huang T, Perez-Cordon G, Feng H, Wei W. Yuan P, et al. Cell Res. 2015 Feb;25(2):157-68. doi: 10.1038/cr.2014.169. Epub 2014 Dec 30. Cell Res. 2015. PMID: 25547119 Free PMC article.

6

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.

Steele J, Mukherjee J, Parry N, Tzipori S. Steele J, et al. J Infect Dis. 2013 Jan 15;207(2):323-30. doi: 10.1093/infdis/jis669. Epub 2012 Nov 2. J Infect Dis. 2013. PMID: 23125448 Free PMC article.

7

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H. Yang Z, et al. Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8. Infect Immun. 2015. PMID: 25486992 Free PMC article.

8

Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.

Sponseller JK, Steele JA, Schmidt DJ, Kim HB, Beamer G, Sun X, Tzipori S. Sponseller JK, et al. J Infect Dis. 2015 Apr 15;211(8):1334-41. doi: 10.1093/infdis/jiu605. Epub 2014 Nov 7. J Infect Dis. 2015. PMID: 25381448 Free PMC article.

9

Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Li S, Shi L, Yang Z, Zhang Y, Perez-Cordon G, Huang T, Ramsey J, Oezguen N, Savidge TC, Feng H. Li S, et al. Infect Immun. 2015 Feb;83(2):502-13. doi: 10.1128/IAI.02316-14. Epub 2014 Nov 17. Infect Immun. 2015. PMID: 25404023 Free PMC article.

10

Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.

Yang Z, Zhang Y, Huang T, Feng H. Yang Z, et al. Gut Microbes. 2015 Jul 4;6(4):221-4. doi: 10.1080/19490976.2015.1062965. Epub 2015 Jun 19. Gut Microbes. 2015. PMID: 26091306 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year